Follow
Ali Tafazzoli
Ali Tafazzoli
Evidera
Verified email at evidera.com
Title
Cited by
Cited by
Year
Skart: A skewness-and autoregression-adjusted batch-means procedure for simulation analysis
A Tafazzoli, JR Wilson
IIE Transactions 43 (2), 110-128, 2010
662010
N-Skart: A nonsequential skewness-and autoregression-adjusted batch-means procedure for simulation analysis
A Tafazzoli, NM Steiger, JR Wilson
IEEE Transactions on Automatic Control 56 (2), 254-264, 2010
412010
Cost‐effectiveness of ivabradine for heart failure in the United States
AR Kansal, MR Cowie, A Kielhorn, S Krotneva, A Tafazzoli, Y Zheng, ...
Journal of the American Heart Association 5 (5), e003221, 2016
352016
Long-term health outcomes of lecanemab in patients with early Alzheimer’s disease using simulation modeling
AA Tahami Monfared, A Tafazzoli, W Ye, A Chavan, Q Zhang
Neurology and therapy 11 (2), 863-880, 2022
322022
Alzheimer's disease Archimedes condition-event simulator: development and validation
AR Kansal, A Tafazzoli, KJ Ishak, S Krotneva, ADNI Collaboration
Alzheimer's & Dementia: Translational Research & Clinical Interventions 4, 76-88, 2018
262018
Performance of Skart: A skewness-and autoregression-adjusted batch means procedure for simulation analysis
A Tafazzoli, JR Wilson, EK Lada, NM Steiger
INFORMS Journal on Computing 23 (2), 297-314, 2011
262011
The potential economic value of lecanemab in patients with early Alzheimer’s disease using simulation modeling
AA Tahami Monfared, A Tafazzoli, A Chavan, W Ye, Q Zhang
Neurology and Therapy 11 (3), 1285-1307, 2022
222022
The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA
A Tafazzoli, SD Ramsey, A Shaul, A Chavan, W Ye, AR Kansal, J Ofman, ...
Pharmacoeconomics 40 (11), 1107-1117, 2022
192022
Cost-effectiveness of DTG+ ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
S Peng, A Tafazzoli, E Dorman, L Rosenblatt, A Villasis-Keever, ...
Journal of medical economics 18 (10), 763-776, 2015
192015
Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors
K Ito, R Chapman, SD Pearson, A Tafazzoli, K Yaffe, JH Gurwitz
JAMA network open 4 (10), e2129392-e2129392, 2021
182021
Performance comparison of MSER-5 and N-Skart on the simulation start-up problem
AC Mokashi, JJ Tejada, S Yousefi, A Tafazzoli, T Xu, JR Wilson, ...
Proceedings of the 2010 Winter Simulation Conference, 971-982, 2010
172010
Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer
A Tafazzoli, S Roberts, R Klein, R Ness, R Dittus
ACM Transactions on Modeling and Computer Simulation (TOMACS) 19 (2), 1-29, 2009
172009
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
A Tafazzoli, OS Reifsnider, L Bellanca, J Ishak, M Carrasco, P Rakonczai, ...
The European Journal of Health Economics 24 (9), 1441-1454, 2023
102023
A comparison of screening methods for colorectal cancer using simulation modeling
A Tafazzoli, SD Roberts, RM Ness, RS Dittus
Proceedings of the Winter Simulation Conference, 2005., 10 pp., 2005
82005
The economic impact of new therapeutic interventions on Neuropsychiatric Inventory (NPI) symptom scores in patients with Alzheimer disease
A Tafazzoli, A Kansal, P Lockwood, C Petrie, A Barsdorf
Dementia and Geriatric Cognitive Disorders Extra 8 (1), 158-173, 2018
62018
A simulation model to evaluate the potential impact of disease-modifying treatments on burden of illness in Alzheimer’s disease
AA Tahami Monfared, A Tafazzoli, W Ye, A Chavan, KA Deger, Q Zhang
Neurology and Therapy 11 (4), 1609-1623, 2022
52022
Cost‐effectiveness of DTG+ ABC/3TC versus EFV/TDF/FTC for first‐line treatment of HIV‐1 in the United States
S Peng, A Tafazzoli, E Dorman, L Rosenblatt, A Villasis‐Keever, ...
Journal of the International AIDS Society 17, 19605, 2014
42014
Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge
RLH Handels, C Green, A Gustavsson, WL Herring, B Winblad, A Wimo, ...
Alzheimer's & Dementia 19 (5), 1800-1820, 2023
32023
Lifetime clinical benefits of lecanemab in early Alzheimer’s disease using simulation modeling
AAT Monfared, A Tafazzoli, W Ye, A Chavan, Q Zhang
Alzheimer’s Dement 18, e069405, 2022
32022
POSB44 Drivers of Value-Based Price (VBP) for a Multi-Cancer Early Detection (MCED) Test
A Tafazzoli, SD Ramsey, A Shaul, A Chavan, W Ye, KC Chung, ...
Value in Health 25 (1), S68, 2022
22022
The system can't perform the operation now. Try again later.
Articles 1–20